Congress Park Capital LLC Acquires 621,908 Shares of Heron Therapeutics, Inc. $HRTX

Congress Park Capital LLC lifted its holdings in shares of Heron Therapeutics, Inc. (NASDAQ:HRTX) by 27.4% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 2,890,157 shares of the biotechnology company’s stock after purchasing an additional 621,908 shares during the quarter. Heron Therapeutics makes up about 1.1% of Congress Park Capital LLC’s holdings, making the stock its 26th biggest position. Congress Park Capital LLC owned approximately 1.58% of Heron Therapeutics worth $3,642,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also modified their holdings of the company. R Squared Ltd bought a new stake in Heron Therapeutics in the second quarter worth $26,000. B. Riley Wealth Advisors Inc. acquired a new stake in shares of Heron Therapeutics in the second quarter worth about $26,000. Russell Investments Group Ltd. bought a new stake in shares of Heron Therapeutics during the 2nd quarter worth about $43,000. ProShare Advisors LLC increased its holdings in shares of Heron Therapeutics by 23.4% during the 2nd quarter. ProShare Advisors LLC now owns 31,368 shares of the biotechnology company’s stock valued at $65,000 after acquiring an additional 5,953 shares during the last quarter. Finally, Prudential Financial Inc. raised its stake in shares of Heron Therapeutics by 231.0% in the 2nd quarter. Prudential Financial Inc. now owns 36,465 shares of the biotechnology company’s stock valued at $75,000 after acquiring an additional 25,450 shares in the last quarter. Institutional investors own 80.01% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts have issued reports on the company. Zacks Research raised Heron Therapeutics from a “strong sell” rating to a “hold” rating in a research report on Tuesday, October 7th. Jefferies Financial Group reaffirmed a “buy” rating on shares of Heron Therapeutics in a report on Tuesday, November 4th. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of Heron Therapeutics in a research note on Wednesday, October 8th. Three research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and an average price target of $4.50.

Heron Therapeutics Stock Down 8.0%

Shares of HRTX stock opened at $1.27 on Thursday. Heron Therapeutics, Inc. has a 12 month low of $1.00 and a 12 month high of $2.68. The company has a quick ratio of 1.78, a current ratio of 2.56 and a debt-to-equity ratio of 19.89. The firm has a market cap of $232.87 million, a PE ratio of -14.11 and a beta of 1.34. The stock has a 50 day moving average of $1.21 and a 200-day moving average of $1.51.

Heron Therapeutics (NASDAQ:HRTX) last announced its quarterly earnings data on Tuesday, November 4th. The biotechnology company reported ($0.05) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.02) by ($0.03). The firm had revenue of $38.21 million for the quarter, compared to analyst estimates of $39.03 million. On average, equities analysts predict that Heron Therapeutics, Inc. will post -0.13 EPS for the current year.

Heron Therapeutics Company Profile

Heron Therapeutics, Inc, a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration.